Release Date: January 30, 2023
Expiration Date: January 30, 2024
Activity Overview
This online, on-demand virtual webcast brings together renowned experts in the diagnosis and treatment of breast cancer to provide a comprehensive overview of noteworthy data presented during the San Antonio Breast Cancer Symposium, held in San Antonio, Texas, in December 2022. In this educational program, these experts discuss and debate the clinical implications and applications of emerging data and the future directions of breast cancer management. Topics include current and emerging treatment options for patients with early-stage and metastatic disease as well as locoregional control using surgery and radiation. This webcast, an extension of the annual School of Breast Oncology®, provides an additional forum for clinicians to keep pace with rapidly emerging data and advancing treatment paradigms in breast cancer.
This educational activity is an archive of the live virtual webcast held on December 15, 2022.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, nurses, and other health care professionals who treat patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine potentially practice-changing efficacy and safety findings from recent clinical trials conducted in early and advanced breast cancer settings
- Describe how recent evidence should be considered in the context of evolving treatment paradigms in breast cancer management and/or how these findings can be incorporated into clinical practice
- Explain how ongoing clinical trials and their designs are intended to move the field forward and bridge clinically unmet needs in breast cancer care
Joyce O’Shaughnessy, MD
Celebrating Women Endowed Chair in Breast Cancer Research
Baylor University Medical Center Chair, Breast Cancer Prevention Research
Texas Oncology Baylor-Sammons Cancer Center
US Oncology Network
Dallas, TX
Disclosures: Consultant: AbbVie, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Athenex, Bayer, Bristol Myers Squibb, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Genzyme, Gilead Sciences, GRAIL, Halozyme Therapeutics, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Lilly, Merck, Myriad, Nektar Therapeutics, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Prime Oncology, Puma Biotechnology, Roche, Samsung Bioepis, Sandoz, Sanofi, Seagen, Syndax Pharmaceuticals, Taiho Oncology, Synthon, Takeda, Theralink.
Terry Mamounas, MD, MPH
Medical Director, Comprehensive Breast Program
Orlando Health Cancer Institute
Professor of Surgery
University of Central Florida
Orlando, FL
Disclosures: Consultant: Exact Sciences, Genentech/Roche, Genzyme-Sanofi, Hologic, Merck, Puma Biotechnology, TerSera; Speaker’s Bureau: Exact Sciences, Genentech/Roche, Merck; Stock/Shareholder: Moderna.
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Disclosures: Grant/Research Support: AMBRX, Astellas Pharma, AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche AG/Genentech, Gilead Sciences, GlaxoSmithKline, Lilly, Merck & Co, Novartis Pharmaceuticals, OBI Pharma, Pfizer, Pionyr Immunotherapeutics, Seagen, Sermonix Pharmaceuticals, Taiho Oncology, Veru; Consultant: Blueprint, Puma, NAPO; Other: (Travel support to academic meetings) Astra Zeneca, Gilead, Merck.
Sara M. Tolaney, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women's Cancer
Senior Physician, Breast Oncology Program
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Grant/Research support: AstraZeneca, Bristol Myers Squibb, Cyclacel Pharmaceuticals, Eisai, Exelixis, Genentech, Gilead/Immunomedics, Lilly, Merck, NanoString Technologies, Nektar Therapeutics, Novartis, Odonate Therapeutics, Pfizer, Sanofi, Seagen. Consultant: 4D Pharma, AstraZeneca, Athenex, BeyondSpring Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, Certara, CytomX Therapeutics, Daiichi Sankyo, Eisai, Ellipses Pharma, G1 Therapeutics, Genentech, Gilead Sciences/Immunomedics, Infinity Pharmaceuticals, Kyowa Kirin Pharmaceuticals, Lilly, Merck, Mersana Therapeutics, NanoString Technologies, Nektar Therapeutics, Novartis, Odonate Therapeutics, OncoPep, OncoSec Medical, Pfizer, Puma Biotechnology, Reveal Genomics, Samsung Bioepis, Sanofi, Seagen Chugai Pharmaceutical, Zentalis Pharmaceuticals, Zymeworks.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here